Payload– tag –
-
AmMax Bio Licenses Lonza’s Conjugation and Linker-Payload Technologies for ADC Program AMB-104
The Pharma Letter USA Overview AmMax Bio announced a non-exclusive licensing agreement with Lonza, a leading CDMO, to utilize Lonza's conjugation and linker-payload technologies. This collaboration aims to support the development of AmMa... -
Rocket Lab Unveils 2026 Electron Launch Schedule, Highlighting iQPS, LOXSAT, and Synspective’s StriX Missions
Smart Calendars AI ニュージーランド Overview Rocket Lab has released its updated launch schedule for mid-2026, featuring a series of Electron rocket missions from both New Zealand and Virginia. This manifest underscores critical deployme... -
Rocket Lab’s HASTE Program to Conduct Hypersonic Test Mission for US DoD DIU in June 2026, Featuring Hypersonix Scramjet
Space Launch Schedule USA Overview Rocket Lab's HASTE (Hypersonic Accelerator Suborbital Test Electron) program, utilizing the Electron rocket as a suborbital testbed for hypersonic research, is scheduled to conduct the "Curveball" missi... -
China’s Chang’e 8 Mission to Test Lunar Construction Robots and ISRU by 2029, Aiming for South Pole Base
Vozpopuli China Overview China's Chang'e 8 mission, scheduled for launch around 2029, will focus on lunar construction robots and In-Situ Resource Utilization (ISRU) experiments near the Moon's South Pole. The mission, comprising a lande... -
WuXi Biologics Completes and Prepares for Operation of New Antibody-Drug Conjugate (ADC) Manufacturing Facility
WuXi Biologics Press Release China Overview WuXi Biologics announced the successful completion and readiness for operation of its new integrated Antibody-Drug Conjugate (ADC) manufacturing facility. This expansion significantly enhances ... -
Henlius Gains NMPA IND Approval for HLX48, a Bispecific c-Met/EGFR Antibody-Drug Conjugate for Solid Tumors
FirstWord Pharma China Overview Shanghai Henlius Biotech, Inc. announced that its self-developed c-Met/EGFR bispecific antibody-drug conjugate (ADC), HLX48, has received Investigational New Drug (IND) approval from China's National Medic... -
NEOK002: Next-Generation Bispecific ADC Targeting EGFR and MUC1 Enters Clinical Development for Solid Tumors
Conference Coverage AACR USA Overview NEOK002 (formerly ABL209), a bispecific antibody-drug conjugate (ADC), has entered clinical development, designed to concurrently target two key cancer antigens, EGFR and MUC1, implicated in epitheli... -
Daiichi Sankyo Records Significant Loss Due to ADC Supply ‘Miscalculation’ Despite Strong Enhertu Sales, Raising Risk Management Questions
東洋経済オンライン Japan Overview Japanese pharmaceutical giant Daiichi Sankyo reported a substantial operating profit decrease for FY2025 despite record sales, attributing a 169.5 billion yen loss provision to compensation for Antibody-... -
Synthetic Small Molecule API Market to See Growth through 2035, Driven by Oncology Pipeline and Generic Demand, Report Says
IndexBox Global Overview This article provides an overview of a market research report published by IndexBox, which forecasts growth in the global synthetic small molecule API market, driven by increasing chronic disease prevalence, a ro...
